2025
TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924).
Ong M, Sokolova A, Hotte S, Dorff T, Chi K, Wyatt A, Goldkorn A, Kolinsky M, Brundage M, Ndika A, Lerner S, Parulekar W, Ding K, Jafri M. TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924). Journal Of Clinical Oncology 2025, 43 DOI: 10.1200/jco.2025.43.16_suppl.tps5129.Peer-Reviewed Original ResearchMetastatic castration sensitive prostate cancerAndrogen receptor pathway inhibitorsAndrogen deprivation therapyPSA responseOverall survivalDisease volumePredictive value of circulating tumor DNADocetaxel to androgen deprivation therapyReceipt of androgen deprivation therapyResponse to androgen deprivation therapyMonths of androgen deprivation therapyAndrogen deprivation therapy initiationCastration sensitive prostate cancerClinical progression free survivalMonths median overall survivalStandard androgen deprivation therapyECOG performance status 0Pathway inhibitorRandomized phase III trialPresence of liver metastasesAbsence of randomized dataRandomized phase III clinical trialsPrimary prostate cancer tissuesNational Clinical Trials NetworkPhase III clinical trials
2024
Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL).
Posadas E, Gay H, Rodgers J, Morgan T, Xiao Y, Yu J, Michalski J, Bouchard M, Desai N, Funk R, Boike T, Jurgens D, Wong A, Shen X, Miyawaki L, Bland C, Hairston J, Sandler H, Pugh S, Feng F. Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL). Journal Of Clinical Oncology 2024, 42: 131-131. DOI: 10.1200/jco.2024.42.4_suppl.131.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression free survivalSalvage radiotherapyHigh-risk featuresBiochemical relapseHigh-risk patientsRadical prostatectomyLHRH analogsDecreased lymphocytesAndrogen receptorMonths of androgen deprivation therapyGrade 3 adverse eventsProgression free survival benefitStandard androgen deprivation therapyMedian follow-up timeGrade 4 AEsPara-aortic radiotherapyProstate cancer patientsEnzalutamide armGleason 9Salvage radiationDeprivation therapyNodal involvementFree survivalRT boostAndrogen deprivation increases frontopolar cortical thickness in prostate cancer patients: an effect of early neurodegeneration?
Chaudhary S, Roy A, Summers C, Ahles T, Li C, Chao H. Androgen deprivation increases frontopolar cortical thickness in prostate cancer patients: an effect of early neurodegeneration? American Journal Of Cancer Research 2024, 14: 3652-3664. PMID: 39113873, PMCID: PMC11301281, DOI: 10.62347/wola8904.Peer-Reviewed Original ResearchFrontopolar cortexCortical thicknessWorking memoryAndrogen deprivation therapyN-back performanceN-back taskProstate cancer patientsYears of educationPublished routinesNeural consequencesBrain changesBrain morphologyMediation analysisCT changesConsequences of androgen deprivation therapyMonths of androgen deprivation therapyTestosterone level changesImpact of androgen deprivation therapyCancer patientsNon-metastatic prostate cancerTestosterone levelsResponse to androgen deprivationLong duration of treatmentBrain imagingNeurodegenerative changes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply